News

Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development
CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...
FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline
Explore FibroGen's Q1 2025 earnings call insights, featuring progress on FG-3246 & FG-3180, extended cash runway, China divestiture updates, & FDA feedback.